Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

A US consumer rights group has said the acting commissioner of the Food and Drug Administration (FDA) Janet Woodcock and other officials should “immediately resign” over the regulator's approval of Biogen Inc's (NASDAQ:BIIB) controversial Alzheimer's drug, aducanumab. In an open letter on Wednesday, Public Citizen, a Washington DC-based special interest group and think tank founded by former presidential candidate Ralph Nader, described the FDA's approval of aducanumab last week as “reckless”, highlighting the “nearly unanimous conclusion of an independent advisory panel of experts that there was insufficient evidence that the drug was effective”.

FDA officials should resign over 'reckless' approval of Biogen Alzheimer's drug, says US NGO

Biogen's newest FDA clearance sent shares soaring, but investors can still buy this stock for as little as $1.

How Has Biogen Soared 61% This Year, But Still Costs Only $1?

Biogen's (BIIB) rare, inherited retinal disease gene therapy candidate, timrepigene emparvovec, fails to meet the primary endpoint in a phase III study.

Biogen (BIIB) 2nd Eye Disease Gene Therapy Misses Study Goal

Biogen Inc. (NASDAQ: BIIB) stock is seeing muted sentiment Tuesday as it emerges from the euphoria over Aduhelm approval, with the most recent trigger being lukewarm data for a partnered program. The Biogen Analyst: Geoff Meacham reiterated a Buy rating on Biogen shares and raised the price target from $400 to $415.

Biogen Analyst Raises Price Target On Higher Chance Of Success For Depression Drug

The company's newly approved drug could generate billions in revenue per year.

Following Its Major Regulatory Win, How Much Upside Does Biogen Have?

The controversy never ends with this biotech's new Alzheimer's drug.

Where Will Biogen Be in 1 Year?

Shares of Biogen Inc. were down 0.3% in premarket trading on Tuesday, the day after the company said an experimental gene therapy for choroideremia failed a late-stage clinical trial. Biogen said Monday that the Phase 3 study did not meet its primary endpoint or efficacy on secondary endpoints among study participants who have the rare, hereditary retinal disease.

Biogen says experimental drug for rare retinal disease fails in late-stage clinical trial

SAGE Therapeutics

Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) have announced data from WATERFALL Phase 3 study evaluating zuranolone (SAGE-217/BIIB125) in patients with Major Depressive Disorder (MDD). The 543-subject trial met its primary endpoint with zuranolone showing statistically significant improvement in depressive symptoms compared with placebo at Day 15.

Sage Therapeutics - Biogen's Zuranolone Tops Placebo In Reducing Depressive Symptoms

Although the company's Alzheimer's drug got approval from the agency, that doesn't mean you should rush out and buy this risky stock.

These 3 Words From the FDA Ensure the Biogen Drama Is Far From Over

Sage Therapeutics Inc. and partner Biogen Inc. said a Phase 3 study of their major depressive disorder (MDD) treatment met its primary endpoint, as it showed "statistically significant improvement" in symptoms compared with placebo. Sage shares slipped 1.9% in premarket trading while Biogen's stock slipped 0.5%.

Sage, Biogen MDD treatment meets primary endpoint

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced that the WATERFALL Study in patients with MDD met its primary endpoint with zuranolone (SAGE-217/BIIB125) 50 mg showing statistically significant improvement in depressive symptoms compared with placebo at Day 15 as assessed by the 17-item Hamilton Rating Scale for Depression (HAMD-17) total score. LS means (SE) change from baseline in HAMD-17 total score at Day 15 for patien

Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder

While basking in the glow of the approval for its Alzheimer's treatment, Biogen Inc (NASDAQ: BIIB) announced that a gene therapy candidate for eye disease failed a late-stage clinical trial, yet again. The company announced topline results from Phase 3 STAR study of timrepigene emparvovec (BIIB111/AAV2-REP1) for choroideremia, a rare inherited retinal disease that results in progressive vision loss.

Yet Another Biogen's Retinal Disease Gene Therapy Fails In Late-Stage Study

CAMBRIDGE, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced topline results from the Phase 3 STAR study of timrepigene emparvovec (BIIB111/AAV2-REP1), an investigational gene therapy for the potential treatment of choroideremia. The STAR study did not meet its primary endpoint of proportion of participants with a ≥15 letter improvement from baseline in best corrected visual acuity (BCVA) at Month 12, in the interventional group in comparison to the non-interventional control group, as measured by the Early Treatment of Diabetic Retinopathy Study (ETDRS) chart. In addition, the study did not demonstrate efficacy on key secondary endpoints. Safety results from the Phase 3 STAR study were consistent with previous studies.

Biogen Announces Topline Results from Phase 3 Gene Therapy Study in Choroideremia

Ingersoll-Rand

Peloton

YETI

Brunswick

Diageo

Squarespace

More than halfway through the trading day, stocks were mixed as the Dow Jones industrials and S&P 500 traded lower while the Nasdaq posted a gain.

Biogen, Ingersoll Rand, Peloton, Yeti and More Monday Afternoon Analyst Research Calls

ARK Genomic Revolution Multi-Sector ETF

Principal Healthcare Innovators Index ETF

Clover Health Investments

First Trust NYSE Arca Biotechnology Index Fund

Global X Genomics & Biotechnology ETF

Orphazyme A/S

ALPS Medical Breakthroughs ETF

Investors may want to tap the bullishness in the sector with the best biotech ETFs of last week.

Top-Performing Biotech ETFs of Last Week

The coming months will offer important clues about long-term revenue.

After a 50% Gain, Is It Too Late to Buy Biogen?

Biogen Alzheimer's drug Aduhelm is the first new treatment for dementia approved by the FDA in decades, and it's started a war over the brain drug pipeline.

Biogen Alzheimer's drug and the battle over dementia treatment of the future

Cara Therapeutics

Ocugen, Inc.

It pays to know what could cause them to move and when.

How to Buy Biotech Stocks This Summer

Shares of Biogen Inc. dropped 4.1% in afternoon trading Friday, to pull back from a six-year high, but UBS analyst Colin Bristow seems room for further gains to a record close. Even with the pullback, the stock has rocketed 39.0% this week, which would be the biggest weekly gain since it ran up 56.3% during the week ending Dec. 23, 1999, after the Food and Drug Administration approved the biotechnology company's Alzheimer's drug, Aduhelm.

Biogen stock heads for biggest weekly rally in more than 2 decades, UBS analyst targets more gains

Biogen (BIIB) stock is dipping lower today on the additional controversy surrounding the approval of its Alzheimer's drug, Aduhelm. The post BIIB Stock: 9 Things to Know About Biogen's Alzheimer Drug Approval Controversy appeared first on InvestorPlace.

BIIB Stock: 9 Things to Know About Biogen's Alzheimer Drug Approval Controversy

The FDA surprised few people but outraged many when it decided to approve Biogen and Eisai's Aducanumab on Monday - the first new Alzheimer's therapy in >20 years. The decision was based on data from two pivotal trials that began in 2016, but failed a futility analysis in 2018. Later data suggested that one trial met all endpoints.

Alzheimer's Approval: How Biogen And FDA Defied The Odds With Aducanumab

The shares of Biogen Inc (NASDAQ:BIIB) are up 1.5% at $421 this morning, following a slew of analyst bull notes, including a hefty price-target hike from J.P.

BIIB Bags Bull Notes After Controversial FDA Decision

A third member of a key Food and Drug Administration advisory panel has resigned over the agency's controversial decision to approve Biogen's new Alzheimer's drug, Aduhelm, CNBC has learned.

Third member of prestigious FDA panel resigns over approval of Biogen's Alzheimer's drug

Biogen Inc. (NASDAQ: BIIB) made history of sorts with the FDA approval for its Alzheimer's treatment Aduhelm. Notwithstanding the still-raging debate over the decision, an analyst at Morgan Stanley is looking past the decision and into key upcoming catalysts that could provide significant upside optionality for Biogen investors.

With Aduhelm Approval Behind Biogen, 5 Catalysts For Investors To Watch

Eli Lilly

Prothena

The FDA's approval of Biogen's Aduhelm in treating Alzheimer's disease boosted all three stocks.

News for Biogen Stock (BIIB)